HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Our top ASX picks in every sector
stocks
Tesla: Shares fall as deliveries come in below consensus
stocks
Will Australia’s dwindling fuel supplies impact this share?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 28.50 | -0.32% |
| CAC 40 | 7,962.39 | 0.00 | 0.00% |
| DAX 40 | 23,168.08 | 130.81 | -0.56% |
| Dow JONES (US) | 46,669.88 | 165.21 | 0.36% |
| FTSE 100 | 10,436.29 | 71.50 | 0.69% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,996.34 | 117.16 | 0.54% |
| Nikkei 225 | 53,385.16 | 28.52 | -0.05% |
| NZX 50 Index | 13,035.03 | 132.88 | 1.03% |
| S&P 500 | 6,611.83 | 29.14 | 0.44% |
| S&P/ASX 200 | 8,704.50 | 25.80 | -0.30% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |